Initiation of antihypertensive monotherapy and incident fractures among Medicare beneficiaries

Table 3 Rates of probable low and normal bone mineral density fractures within 1 year of initiating antihypertensive monotherapy

Drug Class	Probable Low Bone Mineral Density Fractures				Normal Bone Mineral Density Fractures
Drug Class	# Fractures	P-Yrs	Rate Per 10,000 P-Yrs (95% CI)	SMRW HR (95% CI)	# Fractures	P-Yrs	Rate Per 10,000 P-Yrs (95% CI)	SMRW HR (95% CI)
ACE	424	38,157	111 (101, 122)	ref	901	38,157	236 (221, 252)	ref
ARB	99	10,452	95 (77, 115)	0.93 (0.74, 1.17)	237	10,452	227 (199, 257)	0.97 (0.84, 1.13)
BB	464	34,864	133 (121, 146)	1.08 (0.93, 1.26)	969	34,864	278 (261, 296)	1.09 (0.98, 1.21)
CCB	280	17,245	162 (144, 182)	1.13 (0.95, 1.35)	467	17,245	271 (274, 296)	1.09 (0.96, 1.24)
THZ	171	15,273	112 (96, 130)	0.85 (0.68, 1.06)	418	15,273	274 (248, 301)	1.12 (0.98, 1.29)

P-Yrs person-years (calculated by dividing the total number of follow-up days by 365.25)
SMRW Standardized mortality ratio weight, calculated adjusting for all baseline covariates
Incident fracture rates and corresponding 95% CIs were defined as the total number of incident fractures by the total P-Yrs at risk. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using SMR weighted Cox proportional hazard models using a ‘first-treatment-carried-forward’ analysis design. CIs were calculated using robust standard errors to account for the SMRWs”
Probable low bone mineral density fractures included hip and radius fractures. All other non-vertebral fractures were defined as normal bone mineral density fractures
ACE Angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, BB beta blockers, CCB calcium channel blockers, or THZ thiazide diuretics

ISSN: 2197-1714